Willow Biosciences (TSE:WLLW) has released an update.
Willow Biosciences celebrated a transformative fiscal year in 2023, consolidating lab operations in Sunnyvale and achieving a record $1.2 million revenue, marking 43% growth. The company also forged four new partnerships, supporting its momentum into 2024, and made significant strides in its corticosteroid manufacturing platform, anticipating the launch of a new program in the first half of the year.
For further insights into TSE:WLLW stock, check out TipRanks’ Stock Analysis page.